9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inflammasome Deletion Promotes Anti-tumor NK Cell Function in an IL-1/IL-18 Independent Way in Murine Invasive Breast Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Inflammasomes are molecular complexes that trigger an inflammatory response upon detection of pathogens or danger signals. Recent studies suggest that they are also involved in cancer progression. However, their roles during tumorigenesis remain poorly understood and controversial. Here, we investigated whether inflammasome activation supports mammary tumor growth. Using mouse models of invasive breast cancer, our results demonstrate that the absence of a functional inflammasome impairs tumor growth. Importantly, tumors implanted into inflammasome-deficient mice recruited significantly less neutrophils and more natural killer (NK) cells, and these latter cells displayed a more active phenotype. Interestingly, NK cell depletion abolished the anti-tumoral effect observed in inflammasome-deficient mice, although inflammasome-regulated cytokine neutralization had no effect. Thus, our work identifies a novel role for the inflammasome in supporting mammary tumor growth by attenuating NK cell recruitment and activity. These results suggest that inflammasome inhibition could be a putative target for treating invasive breast cancers.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

          Summary Conventional type 1 dendritic cells (cDC1) are critical for antitumor immunity, and their abundance within tumors is associated with immune-mediated rejection and the success of immunotherapy. Here, we show that cDC1 accumulation in mouse tumors often depends on natural killer (NK) cells that produce the cDC1 chemoattractants CCL5 and XCL1. Similarly, in human cancers, intratumoral CCL5, XCL1, and XCL2 transcripts closely correlate with gene signatures of both NK cells and cDC1 and are associated with increased overall patient survival. Notably, tumor production of prostaglandin E2 (PGE2) leads to evasion of the NK cell-cDC1 axis in part by impairing NK cell viability and chemokine production, as well as by causing downregulation of chemokine receptor expression in cDC1. Our findings reveal a cellular and molecular checkpoint for intratumoral cDC1 recruitment that is targeted by tumor-derived PGE2 for immune evasion and that could be exploited for cancer therapy.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Targeting the NLRP3 inflammasome in inflammatory diseases

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Natural killer cells and other innate lymphoid cells in cancer

              Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most immunomodulatory strategies focus on enhancing T cell responses, but there has been a recent surge of interest in harnessing the relatively underexplored natural killer (NK) cell compartment for therapeutic interventions. NK cells show cytotoxic activity against diverse tumour cell types, and some of the clinical approaches originally developed to increase T cell cytotoxicity may also activate NK cells. Moreover, increasing numbers of studies have identified novel methods for increasing NK cell antitumour immunity and expanding NK cell populations ex vivo, thereby paving the way for a new generation of anticancer immunotherapies. The role of other innate lymphoid cells (group 1 innate lymphoid cell (ILC1), ILC2 and ILC3 subsets) in tumours is also being actively explored. This Review provides an overview of the field and summarizes current immunotherapeutic approaches for solid tumours and haematological malignancies.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                16 September 2020
                2020
                : 10
                : 1683
                Affiliations
                [1] 1Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Université de Lyon, Université Lyon 1, Centre Léon Bérard , Lyon, France
                [2] 2Centre International de Recherche en Infectiologie, INSERM U1111 – CNRS UMR5308, Université de Lyon, ENS de Lyon, Université Lyon 1 , Lyon, France
                Author notes

                Edited by: Francois Ghiringhelli, Institut National de la Santé et de la Recherche Médicale (INSERM), France

                Reviewed by: Limagne Emeric, Centre Georges François Leclerc, France; Frederique Vegran, INSERM U1231 Lipides, Nutrition, Cancer (LNC), France; Antonino Bruno, MultiMedica (IRCCS), Italy

                *Correspondence: Virginie Petrilli virginie.petrilli@ 123456lyon.unicancer.fr

                This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology

                †Present address: Baptiste Guey, Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

                Isabelle Puisieux, Institut Curie, Research Center U932 26, rue d'ULM 75248, Paris, France

                Article
                10.3389/fonc.2020.01683
                7526436
                33042810
                4bad963c-a8ba-494f-b6f0-18f9d44289e8
                Copyright © 2020 Guey, Bodnar-Wachtel, Drouillard, Eberhardt, Pratviel, Goutagny, Bendriss-Vermare, Puisieux, Caux, Walzer and Petrilli.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 22 May 2020
                : 29 July 2020
                Page count
                Figures: 6, Tables: 0, Equations: 0, References: 64, Pages: 11, Words: 7371
                Funding
                Funded by: Ligue Contre le Cancer 10.13039/501100004099
                Funded by: Fondation ARC pour la Recherche sur le Cancer 10.13039/501100004097
                Categories
                Oncology
                Original Research

                Oncology & Radiotherapy
                inflammasome,breast cancer,nk cells,inflammation,caspase-1,asc
                Oncology & Radiotherapy
                inflammasome, breast cancer, nk cells, inflammation, caspase-1, asc

                Comments

                Comment on this article